340 related articles for article (PubMed ID: 9667767)
1. Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors.
Petitet F; Jeantaud B; Reibaud M; Imperato A; Dubroeucq MC
Life Sci; 1998; 63(1):PL1-6. PubMed ID: 9667767
[TBL] [Abstract][Full Text] [Related]
2. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study.
Oviedo A; Glowa J; Herkenham M
Brain Res; 1993 Jul; 616(1-2):293-302. PubMed ID: 8395305
[TBL] [Abstract][Full Text] [Related]
3. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
Pertwee RG
Br J Pharmacol; 2008 Jan; 153(2):199-215. PubMed ID: 17828291
[TBL] [Abstract][Full Text] [Related]
4. Comparison of cannabinoid binding sites in guinea-pig forebrain and small intestine.
Ross RA; Brockie HC; Fernando SR; Saha B; Razdan RK; Pertwee RG
Br J Pharmacol; 1998 Nov; 125(6):1345-51. PubMed ID: 9863666
[TBL] [Abstract][Full Text] [Related]
5. delta9-Tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors.
French ED
Neurosci Lett; 1997 May; 226(3):159-62. PubMed ID: 9175591
[TBL] [Abstract][Full Text] [Related]
6. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro.
Thomas A; Baillie GL; Phillips AM; Razdan RK; Ross RA; Pertwee RG
Br J Pharmacol; 2007 Mar; 150(5):613-23. PubMed ID: 17245363
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5'-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranes.
Griffin G; Atkinson PJ; Showalter VM; Martin BR; Abood ME
J Pharmacol Exp Ther; 1998 May; 285(2):553-60. PubMed ID: 9580597
[TBL] [Abstract][Full Text] [Related]
8. Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat.
Craft RM; Wakley AA; Tsutsui KT; Laggart JD
J Pharmacol Exp Ther; 2012 Mar; 340(3):787-800. PubMed ID: 22182934
[TBL] [Abstract][Full Text] [Related]
9. Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats.
Parker LA; Burton P; Sorge RE; Yakiwchuk C; Mechoulam R
Psychopharmacology (Berl); 2004 Sep; 175(3):360-6. PubMed ID: 15138755
[TBL] [Abstract][Full Text] [Related]
10. Relationships between ligand affinities for the cerebellar cannabinoid receptor CB1 and the induction of GDP/GTP exchange.
Kearn CS; Greenberg MJ; DiCamelli R; Kurzawa K; Hillard CJ
J Neurochem; 1999 Jun; 72(6):2379-87. PubMed ID: 10349847
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of hippocampal acetylcholine release after acute and repeated Delta9-tetrahydrocannabinol in rats.
Carta G; Nava F; Gessa GL
Brain Res; 1998 Oct; 809(1):1-4. PubMed ID: 9795096
[TBL] [Abstract][Full Text] [Related]
12. Time course of the effects of different cannabimimetics on prolactin and gonadotrophin secretion: evidence for the presence of CB1 receptors in hypothalamic structures and their involvement in the effects of cannabimimetics.
Fernández-Ruiz JJ; Muñoz RM; Romero J; Villanua MA; Makriyannis A; Ramos JA
Biochem Pharmacol; 1997 Jun; 53(12):1919-27. PubMed ID: 9256167
[TBL] [Abstract][Full Text] [Related]
13. Delta9-tetrahydrocannabinol increases sequence-specific AP-1 DNA-binding activity and Fos-related antigens in the rat brain.
Porcella A; Gessa GL; Pani L
Eur J Neurosci; 1998 May; 10(5):1743-51. PubMed ID: 9751146
[TBL] [Abstract][Full Text] [Related]
14. Two distinctive antinociceptive systems in rats with pathological pain.
Mao J; Price DD; Lu J; Keniston L; Mayer DJ
Neurosci Lett; 2000 Feb; 280(1):13-6. PubMed ID: 10696800
[TBL] [Abstract][Full Text] [Related]
15. Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain.
Burkey TH; Quock RM; Consroe P; Ehlert FJ; Hosohata Y; Roeske WR; Yamamura HI
Eur J Pharmacol; 1997 Oct; 336(2-3):295-8. PubMed ID: 9384246
[TBL] [Abstract][Full Text] [Related]
16. Reversal of cannabinoids (delta9-THC) by the benzoflavone moiety from methanol extract of Passiflora incarnata Linneaus in mice: a possible therapy for cannabinoid addiction.
Dhawan K; Kumar S; Sharma A
J Pharm Pharmacol; 2002 Jun; 54(6):875-81. PubMed ID: 12079005
[TBL] [Abstract][Full Text] [Related]
17. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism.
Tanda G; Pontieri FE; Di Chiara G
Science; 1997 Jun; 276(5321):2048-50. PubMed ID: 9197269
[TBL] [Abstract][Full Text] [Related]
18. (-)-Delta9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase.
Bayewitch M; Rhee MH; Avidor-Reiss T; Breuer A; Mechoulam R; Vogel Z
J Biol Chem; 1996 Apr; 271(17):9902-5. PubMed ID: 8626625
[TBL] [Abstract][Full Text] [Related]
19. Local administration of delta9-tetrahydrocannabinol attenuates capsaicin-induced thermal nociception in rhesus monkeys: a peripheral cannabinoid action.
Ko MC; Woods JH
Psychopharmacology (Berl); 1999 Apr; 143(3):322-6. PubMed ID: 10353438
[TBL] [Abstract][Full Text] [Related]
20. Effects of chronic treatment with delta9-tetrahydrocannabinol on cannabinoid-stimulated [35S]GTPgammaS autoradiography in rat brain.
Sim LJ; Hampson RE; Deadwyler SA; Childers SR
J Neurosci; 1996 Dec; 16(24):8057-66. PubMed ID: 8987831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
